Bioequivalence evaluation of two brands of lisinopril tablets (Lisotec and Zestril) in healthy human volunteers

Biopharmaceutics and Drug Disposition

Volumn 26, Issue 8, 2005, Pages 335-339

  Tamimi, J J I ^a   Salem, I I ^a   Alam, S Mahmood ^b   Zaman, Q ^b   Dham, Ruwayda ^b  

^a Arab Company for Drug Industries & Medical Appliances   (Jordan)

^b Gulf Pharmaceutical Industries   (United Arab Emirates)

Author keywords

Bioequivalence; HPLC; Julphar; Lisinopril; Pharmacokinetics

Indexed keywords

LISINOPRIL; LISOTEC;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MASS SPECTROMETRY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET; VOLUNTEER;

ADOLESCENT; ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CROSS-OVER STUDIES; HUMANS; LISINOPRIL; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 28044441123     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.465     Document Type: Article

References (16)

1. Brunner DB, Desponds G, Biollar J, et al. Effect of a new angiotensin-converting enzyme inhibitor MK-421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol 1981; 11: 461-467.
2. Rotmensch HH, Vincent M, Vlasses PH, et al. Initial evaluation of the non-sulfhydryl-containing converting enzyme inhibitor MK-521 in hypertensive humans. Fed Proc 1984; 43: 1333-1335.
3. Sean CS (ed.). Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Denver, CO, Vol. 122 expires 12/2004.
4. Index Nominum: International Drug Directory. Edited by the Swiss Pharmaceutical Society © 2000. Medpharm Scientific Publishers, Stuttgart, Germany, Micromedex, Inc, Denver, CO, Vol. 122 expires 12/2004.
5. Gomez HJ, Cirillo VJ, Moncloa F. The clinical pharmacology of lisinopril. J Cardiovasc Pharmacol 1987; 9(Suppl 3): S27-S34.
6. Product Information: Prinivil(R), lisinopril. Merck & Co., Inc., Whitehouse Station, NJ (PI revised 4/2003) reviewed 10/2003. Micromedex, Inc, Denver, CO, Vol. 122 expires 12/2004.
7. Ajayi AA, Campbell BC, Kelman AW, et al. Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril. Int J Clin Pharmacol Res 1985; 6: 419-427.
8. Ulm EH, Hichens M, Gomez HJ, et al. Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol 1982; 14: 357-362.
9. Greenbaum R, Zucchelli P, Caspi A, et al. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency. Br J Clin Pharmacol 2000; 49: 23-31.
10. Gascon AR, Cuadrado A, Solinis MA, et al. Comparative bioavailability of two immediate-release tablets of lisinopril/hydrochlorothiazide in healthy volunteers. Int J Clin Pharmacol Ther 2003; 41: 309-315.
11. Shah VP, Midha KK, Dighe S, et al. Analytical method validation: bioavailability, bioequivalence and pharmacokinetic studies. Eur J Drug Metab Pharmacokinet 1992; 16: 249-255.
12. KineticaTM 2000. Version 3.0, Innaphase, User Manual, 1999.
13. FDA Guidelines. Bioequivalence Food and Drug Administration, Division of Bioequivalence, Office of Generic Drugs. Rockville, MD. 1 July 1992 Guidelines. Gascon AR, Cuadrado A, Solinis MA, Hernandez RM, Ramirez E, Dalmau R, Pedraz JL. Comparative bioavailability of two immediate-release tablets of lisinopril/hydrochlorothiazide in healthy volunteers. Int J Clin Pharmacol Ther 2003; 41: 309-315.
14. Grahnen A. Design of bioavailability studies. Pharm Int 1984; 5: 100-103.
15. Westlake WJ. Bioavailability and bioequivalence of pharmaceutical formulations. In Biopharmaceutical Statistics for Drug Development, Peace KE (ed.). Marcel Dekker: New York, 1988; 329-352.
16. Chow CS, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies. Marcel Dekker: New York, 1992.